Supreme Court backs Delhi HC orders in Daiichi-Fortis dispute, clears way for forensic audit

The Supreme Court has declined to interfere with Delhi High Court orders in the long-running Daiichi Sankyo-Fortis dispute, allowing a forensic audit to proceed as part of efforts to trace assets linked to enforcement of a 2016 arbitral award against former Fortis promoters. The apex court did not examine the merits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MsfkSCY
via IFTTT

Read More

Alkem Laboratories CFO Nitin Agrawal resigns

Alkem Laboratories CFO and Key Managerial Personnel Nitin Agrawal has resigned from the drug maker to pursue new professional opportunities, the company said in a regulatory filing. Agrawal will step down from his senior management position effective September 30, 2026. He cited long-term professional and personal growth in his resignation letter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WQ9gku1
via IFTTT

Read More

HLL Lifecare to expand pharmacy network to 600 outlets, add 4,500 jobs

HLL Lifecare Ltd intends to broaden its pharmacy network to 600 outlets nationwide over the coming year, creating around 4,500 job opportunities in healthcare. With around 340 existing stores, HLL champions affordable healthcare solutions while ensuring vital services reach all citizens. Notably, this expansion will roll out just in time for World Pharmacists Day on September 25.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QnXliu9
via IFTTT

Read More

Goldman Sachs picks up stake in Lord’s Mark Industries Limited

Lord’s Mark Industries Limited has garnered impressive interest from investors following the sale of approximately 1 crore shares by its promoter. This strategic move was intended to meet SEBI’s Minimum Public Shareholding norms, boosting the company’s visibility in the market. Prominent investors like Goldman Sachs Investments Mauritius I and AT Trade Overseas took part in this endeavor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PLw2EHT
via IFTTT

Read More

Zydus Lifesciences expects decent growth for five years as innovation matures: Sharvil Patel

Zydus Lifesciences is transitioning from a traditional pharmaceutical company to a more patient-driven organization. The company plans to focus on specialty medicines and biotechnology innovation. It aims to achieve double-digit revenue growth and improved profitability over the next five years. Zydus intends to enhance its oncology franchise and explore partnerships for novel biologics. The expected contributions from discovery-led products will materialize from 2030 onwards, strengthening its market position.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NYwr5pR
via IFTTT

Read More

Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD

"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business and Saroglitazar and maybe something more as well. In the next four to five years we will definitely see meaningful value being created from these."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e0dODfu
via IFTTT

Read More

How India’s smaller hospitals are becoming the next big digital health market

Smaller hospitals in India are becoming the new digital health market. As the Ayushman Bharat Digital Mission expands, the demand for digital solutions had increased. Healthcare tech companies are focusing on providing solutions tailored to smaller providers. Despite challenges in implementation, the integration into existing workflows could improve patient experiences significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Uz3Gadq
via IFTTT

Read More